louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT03841877: Color Dental Alteration Caused by Endodontic Treatment
Official title: Color Dental Alteration Caused by Endodontic Treatment
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: NA
Conditions: Endodontically Treated Teeth
Tooth Discoloration
Root Canal Infection
Lead sponsor: Federal University of Pelotas
Sponsor class: OTHER
First posted: 2019-02-15
Enrollment: 0
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The color change of endodontically treated teeth is a common concern in clinical practice. The objective of this study will be to evaluate, in vivo, the color change (ΔE00) caused by endodontic treatment. A randomized clinical trial (RCT) will be conducted with the objective of evaluating ΔE00 originated from epoxy resin (AH Plus) and mineral trioxide aggregate (MTA Fillapex) endodontic sealers, sectioned at the cervical level and 2 mm below, in a period between the immediate endodontic treatment versus after 3, 6 and 12 months.

Detailed description: The sample syze determined that 48 anterior teeth (incisors and canines) and posterior teeth (premolars) should be included in the study. The sealer and cut will be randomly determined at time of endodontic treatment, originating four groups (n = 12): AH Plus-Cervical, MTA Fillapex-Cervical, AH Plus-2mm and MTA-2mm. The endodontic access cavities will be sealed with resin composed of the color of the dental element. The mean, standard deviation and confidence interval (CI 95%) of the values of ΔE00 obtained for each sealer will be initially analyzed using the variable cut level (cervical or 2mm) using the T test. Indeed, the values of ΔE00 will be analyzed by two-way analysis of variance, where the level of the cut and the type of sealer will be the factors under study.

Eligibility criteria: Inclusion Criteria:

endodontically treated tooth, without intraradicular retainer and fixation;

* presence of homologous tooth to that treated, with pulp vitality and at least 1/3 of the crown;
* correctly patient's file showing the endodontic treatment day, the endodontic filler used, the pulp condition at the first consultation, and periapical radiography, obtained with the use of a radiographic positioner, preserved and with a clear apical image

Exclusion Criteria:

* dental elements submitted to retreatment;
* files with insufficient data, and absence of quality periapical radiography

Primary outcomes:
measure: Color change
timeFrame: After immediate endodontic treatment versus after 3, 6 and 12 months
Secondary outcomes:
Other outcomes:
Locations:
city: Pelotas
country: Brazil
facility: Federal University of Pelotas
state: RS
Study officials:
References:
Clinical trial NCT05810077: Feasibility of Brachial Plexus Ultrasound in Evaluation of Patients With Brachial Plexus Injuries
Official title: Feasibility of Brachial Plexus Ultrasound in Evaluation of Patients With Brachial Plexus Injuries
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Brachial Plexus Injury
Lead sponsor: Assiut University
Sponsor class: OTHER
First posted: 2023-04-12
Enrollment: 36
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: CROSS_SECTIONAL
Sampling method: PROBABILITY_SAMPLE
Study population: Study sample calculated using Epi . as 36 patients.

Brief summary: Evaluation of ultrasound as a diagnostic tool in assessment of patients with brachial plexus injuries before undergoing surgical exploration

Detailed description: Ultrasound of the brachial plexus is particularly good for assessing brachial plexus injuries, nerve sheath tumors,perineural fibrosis, metastasis, some inflammatory neuropathies, neuralgic amyotrophy and post traumatic sequele

Eligibility criteria: Inclusion Criteria:

* all patients ages with brachial plexus injuries

Exclusion Criteria:

* patients underwent brachial plexus surgery before
* patients with surgical emphysema
* patients with serious skeletal malformations

Primary outcomes:
measure: Number of patients with positive ultrasound findings of brachial plexus injuries ( nerve root avulsion, nerve rupture) .
timeFrame: Within 2 weeks
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: Assist university
name: Hager M Ahmed, Master
role: PRINCIPAL_INVESTIGATOR
affiliation: Assist university
name: Nagham N Mahmood, Professor
role: STUDY_CHAIR
References:
Clinical trial NCT02995577: Biomarkers for Feeding Intolerance in Infants With Complex Congenital Heart Defects Undergoing Single Ventricle Staged Palliation
Official title: Biomarkers for Feeding Intolerance in Infants With Complex Congenital Heart Defects Undergoing Single Ventricle Staged Palliation
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Single Ventricle Physiology
Lead sponsor: The University of Texas Health Science Center, Houston
Sponsor class: OTHER
First posted: 2016-12-16
Enrollment: 30
Sex: ALL
Minimum age (years): 1
Maximum age (years): 3
Standard ages: CHILD
Accepts healthy volunteers: no
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: The study population will be infants with complex congenital cyanotic heart disease requiring single ventricle staged palliation surgery at Children's Memorial Hermann Hospital (CMHH) at the Texas Medical Center. This will include neonates undergoing single ventricle staged palliation in the form of (a) Norwood-type procedure, (b) systemic-to-pulmonary artery shunt procedure, or (c) pulmonary artery banding.

Brief summary: The purpose of this study is to investigates serum and stool biomarkers as predictors for post-operative feeding intolerance in infant patients with complex congenital heart defects who undergo single ventricle staged palliation surgery.


Eligibility criteria: Inclusion Criteria:

* Full term gestational period (37 weeks gestation or greater)
* minimum of 2.5kg or greater body weight
* diagnosis of single ventricle physiology, or complex congenital cyanotic heart disease requiring staged palliation surgery in the form of Norwood-type procedure, systemic-to-pulmonary artery shunt, or pulmonary artery banding.

Exclusion Criteria:

* Have diseases affecting other organs,
* have major congenital anomalies such as Hirschsprung disease, imperforate anus, CHARGE syndrome, or VACTERL association.

Primary outcomes:
measure: Level of most abundant serum protein as determined by ELISA
timeFrame: baseline (3-5 days after initial cardiac surgery), within three weeks of the initial cardiac surgery
measure: Level of second most abundant serum protein as determined by ELISA
timeFrame: baseline (3-5 days after initial cardiac surgery), within three weeks of the initial cardiac surgery
measure: Level of stool biomarker interleukin-8 (IL-8) as determined by ELISA
timeFrame: baseline (3-5 days after initial cardiac surgery), within three weeks of the initial cardiac surgery
measure: Level of stool biomarker calprotectin as determined by ELISA
timeFrame: baseline (3-5 days after initial cardiac surgery), within three weeks of the initial cardiac surgery
Secondary outcomes:
Other outcomes:
Locations:
city: Houston
country: United States
facility: The University of Texas Health Science Center at Houston
state: Texas
Study officials:
affiliation: The University of Texas Health Science Center, Houston
name: Supriya Nair, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02073253: Noninvasive Ventilation and Thoracic-abdominal Kinematics in Heart Failure Patients
Official title: Effect of Noninvasive Ventilation in Thoracic-abdominal Kinematics of Individuals With Heart Failure Associated With Cardiomegaly: a Randomized Controlled Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Heart Failure
Lead sponsor: Universidade Federal de Pernambuco
Sponsor class: OTHER
Collaborators: name: Pronto Socorro Cardiológico de Pernambuco-PROCAPE
First posted: 2014-02-27
Enrollment: 24
Sex: ALL
Minimum age (years): 18
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: Introduction: Noninvasive ventilation (NIV) has been used to minimize such impairment and increasing ventilator reserve in individuals with heart failure. Aim: To analyze thoracoabdominal kinematics (TK) in individuals with HF associated to cardiomegaly after using NIV. Methods: A randomized crossover clinical trial with allocation consisted of two experimental phases: NIV and control, 7 days apart of each other. During NIV phase, 30 minutes of bi-level ventilation was performed. Any type of ventilator support was offered during control phase. Optoeletronic plethismography was performed to asses TK.


Eligibility criteria: Inclusion Criteria:

* body mass index (BMI) \<30 kg/m2
* functional class II-III according to the New York Heart Association
* of the echocardiogram últiimos 6 months showing ejection fraction (LVEF) ≤ 45%,
* últiimos echocardiogram of six months showing cardiac hypertrophy (left Ventricular Diastolic Diameter (LVDD)\> 55mm, Diameter Systolic left Ventricular (LVSD)\> 45mm ),
* (optimized from the point of view of drug,
* clinical stability.

Exclusion Criteria:

* unstable angina, myocardial infarction or heart surgery three months before the beginning of the research,
* chronic orthopedic, infectious or metabolic diseases,
* FEV1/FVC \<70% predicted characterizing obstructive respiratory disorder;
* active smokers;
* Limitation on the use of NIV: claustrophobia, inability to remain with their mouths closed, abdominal distention, hemodynamic instability, heart rate (HR) \<60 bpm, recent trauma, nausea and vomiting face.

Primary outcomes:
measure: Thoraco-abdominal kinematics
timeFrame: Seven days
Secondary outcomes:
measure: Other ventilatory responses
timeFrame: Seven days
Other outcomes:
Locations:
city: Recife
country: Brazil
facility: Departamento de Fisioterapia da UFPE
state: Pernambuco
Study officials:
References:
citation: Olson TP, Johnson BD. Influence of cardiomegaly on disordered breathing during exercise in chronic heart failure. Eur J Heart Fail. 2011 Mar;13(3):311-8. doi: 10.1093/eurjhf/hfq177. Epub 2010 Oct 16.
Clinical trial NCT00491153: Sensitivity and Specificity of Aridol Challenge for a Diagnosis of Asthma by a Specialist Pulmonologist
Official title: Sensitivity and Specificity of Aridol Challenge for a Diagnosis of Asthma by a Specialist Pulmonologist
Study type: OBSERVATIONAL
Overall status: TERMINATED
Conditions: Asthma
Keywords: asthma
airway hyperresponsiveness
dry powder mannitol inhalation
methacholine
Lead sponsor: St. Olavs Hospital
Sponsor class: OTHER
Collaborators: name: Haukeland University Hospital
First posted: 2007-06-25
Enrollment: 35
Sex: ALL
Minimum age (years): 16
Maximum age (years): 50
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Patients with a tentative diagnosis of asthma or suspected asthma referred to a pulmonologist for evaluation

Brief summary: The purpose of this study is to estimate the sensitivity, specificity and positive and negative predictive values of a positive Aridol challenge with respect to a specialist pulmonologist diagnosis of asthma in corticosteroid naive subjects with asthma-like symptoms and no previous diagnosis of asthma. The comparator is methacholine provocation


Eligibility criteria: Inclusion Criteria:

* Informed consent
* Provisional or possible asthma diagnosis
* FEV1 at least 70% of predicted at inclusion

Exclusion Criteria:

* Contraindications for bronchial provocation challenge or spirometry
* Respiratory tract infection within previous 6 weeks
* Significant co-morbidity
* \> 10 pack year smoking history
* Other lung diseases
* Pregnancy, lactation

Primary outcomes:
measure: sensitivity, specificity and positive and negative predictive values of a positive Aridol bronchial challenge test
timeFrame: 1 day
Secondary outcomes:
Other outcomes:
Locations:
city: Trondheim
country: Norway
facility: St.Olavs Hospital, University Hospital of Trondheim
state: South Trøndelag
city: Trondheim
country: Norway
facility: Dr Alf Magne Heggli medical practice
state: South Trøndelag
city: Bergen
country: Norway
facility: Haukeland University Hospital
Study officials:
affiliation: Haukeland University Hospital
name: Ernst Omenaas, MD, PhD
role: STUDY_DIRECTOR
References:
citation: Anderson SD, Charlton B, Weiler JM, Nichols S, Spector SL, Pearlman DS; A305 Study Group. Comparison of mannitol and methacholine to predict exercise-induced bronchoconstriction and a clinical diagnosis of asthma. Respir Res. 2009 Jan 23;10(1):4. doi: 10.1186/1465-9921-10-4.
Clinical trial NCT00816153: Pleth Variability Index and Fluid Management During Surgery
Official title: Is Pleth Variability Index Able to Guide Fluid Management During Surgery?
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Fluid Management
Keywords: Pleth variability Index
Fluid management
Fluid management during surgery
Lead sponsor: Université Catholique de Louvain
Sponsor class: OTHER
Collaborators: name: Masimo Corporation
First posted: 2008-12-31
Enrollment: 97
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Pleth Variability Index (PVI) seems to be an ideal parameter to guide fluid management: dynamic parameter and non-invasive. PVI could guide fluid management during surgery and optimization of the plethysmographic-derived parameter could improve hemodynamics of the patients.


Eligibility criteria: Inclusion Criteria:

* Major abdominal surgery

Exclusion Criteria:

* Refusal or inability to understand the protocol
* Arrythmia
* \<18 years
* Contraindication to normal mechanical ventilation

Primary outcomes:
measure: Hemodynamics and derived-parameters
timeFrame: The first 48 h
Secondary outcomes:
measure: All causes of morbi-mortality
Other outcomes:
Locations:
city: Brussels
country: Belgium
facility: St-Luc Hospital
Study officials:
References:
Clinical trial NCT06584253: Digital Addiction Among University Students
Official title: Relationship of Multidimensional Factors with Digital Addiction Among University Students: a Cross-Sectional Study
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Internet Addiction
University Student
Lead sponsor: Inonu University
Sponsor class: OTHER
First posted: 2024-09-04
Enrollment: 32
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: OTHER
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: University students

Brief summary: The aim of this study is to contribute to our understanding of digital media addiction by investigating the prevalence of digital addiction among university students and examining the relationship between variables such as body awareness, physical activity levels, hand grip strength, upper extremity function and pain-dash, quality of life, depression, stress, anxiety, sleep quality, and cognitive levels and digital addiction.

Detailed description: After recording the demographic information of all individuals participating in the study, screen addiction, BMI, body awareness, physical activity levels, handgrip strength, upper extremity pain and function and pain-dash, quality of life, depression, stress, anxiety, sleep quality, cognitive levels will be evaluated. Individuals will be asked to fill out self-report questionnaires.

Eligibility criteria: Inclusion Criteria:

* University students aged 18 and over
* Those who have been using smartphones for more than a year

Exclusion Criteria:

* People under the age of 18,
* Those diagnosed by a doctor with any musculoskeletal, rheumatic, neurological, cardiovascular system diseases or diagnosed with a mental disorder, sleep disorder such as narcolepsy or addiction to alcohol, substances, etc.
* Those with any history of injury or surgery in the upper extremity

Primary outcomes:
measure: Musculoskeletal System Health Questionnaire Scale
timeFrame: 24-48 hours
measure: International Physical Activity Questionnaire (short form)
timeFrame: 24-48 hours
measure: Pittsburgh Sleep Quality Index
timeFrame: 24-48 hours
measure: Cognitive Failures Questionnaire
timeFrame: 24-48 hours
measure: Jamar hand dynamometer
timeFrame: 24-48 hours
measure: Depression Anxiety Stress Scale - 21 Short Form
timeFrame: 24-48 hours
measure: Body Awareness Questionnaire
timeFrame: 24-48 hours
measure: SF-12
timeFrame: 24-48 hours
measure: Digital Addiction Scale
timeFrame: 24-48 hours
Secondary outcomes:
Other outcomes:
Locations:
city: Iğdır
country: Turkey
facility: Dilan Demirtas Karaoba
state: Igdir
city: Igdir
country: Turkey
facility: Dilan
state: Iğdır
Study officials:
affiliation: Inonu University
name: dilan demirtas karaoba, asst. prof
role: STUDY_DIRECTOR
References:
Clinical trial NCT05232253: Cystoealstometer (Bladder Monitor Device)-Home Use
Official title: Measurement of Bladder Pressure With a Novel External Device (Cystoealstometer) - Home
Study type: INTERVENTIONAL
Overall status: ACTIVE_NOT_RECRUITING
Phase: NA
Conditions: Urinary Bladder, Neurogenic
Keywords: urodynamics
neurogenic
bladder
Lead sponsor: University of Iowa
Sponsor class: OTHER
First posted: 2022-02-09
Enrollment: 30
Sex: ALL
Minimum age (years): 6
Maximum age (years): 99
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: OTHER

Brief summary: The investigators have developed a novel pressure monitoring device called a 'cystoelastometer' that connects to a drainage end ofastandard urinary catheters that are used by patients with a neurogenic bladder on daily clean intermittent catheterization. The device has already been demonstrated to be accurate in measuring bladder pressure compared to the gold standard urodynamics that are performed in the clinic or hospital. This study will assess the patients and care givers ability and experience using the cystoelastometer device in a home setting.

Detailed description: : For patients with neurogenic bladder, regular monitoring of bladder pressure and capacity is a critical component of maintaining renal and urinary health. This monitoring is currently done by in-office urodynamics testing (UDS). This testing is done intermittently, leaving open the possibility of worsening of bladder function and renal deterioration between testing sessions.

This study utilizes a novel pressure and bladder volume monitoring device which is portable and attaches to the end of a standard urinary catheter and measures the pressure in the device and then assists in the drainage of the bladder and records the bladder volume. The investigators will be investigating if this device can be used by patients or their caregivers in a home setting.

This study will enroll patients with neurogenic bladder that currently perform clean intermittent catheterization on a daily basis as part of their regular care. The patients will be asked to use the device at least twice a day for two weeks.

Eligibility criteria: Inclusion Criteria:

* Patients seen in the University of Iowa Pediatric Urology Clinic with neurogenic bladder managed with clean intermittent catheterization.
* Patients who haven't had any change in management
* Patients who had recently had UDS (urodynamic study) performed

Exclusion Criteria:

* phone which is not iOS compatible

Primary outcomes:
measure: Home use of bladder pressure and volume monitoring device- Cystoelastometer
timeFrame: Two weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Iowa City
country: United States
facility: University of Iowa Hospital and Clinics
state: Iowa
Study officials:
affiliation: University of Iowa
name: Christopher S Cooper, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01089153: Obtaining and Storing Human Blood, Urine, and Fecal Samples for Spirochete-Related Epidemiological Research
Official title: Obtaining and Storing Human Blood, Urine, and Fecal Samples for Spirochete-Related Epidemiological Research
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: The Samples Will be Studied in Order to Attempt to Better Understand the Occurrence of Blood, Feces and Urine Borne Spirochaetes
Keywords: human blood, urine and fecal samples
Lead sponsor: Southwest Regional Wound Care Center
Sponsor class: OTHER
First posted: 2010-03-18
Enrollment: 35
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Blood, feces and urine samples may be collected from subjects with known or suspected spirochetal disease or from subjects not suspected to be infected with spirochetes

Brief summary: Current spirochaete infection identification and diagnostic strategies have important limitations. Recent development may allow for an improvement in diagnostic, screening and survey capabilities. The goal of this study is to evaluate blood, urine and fecal samples from a variety of sources and generate information on the occurrence and epidemiology of spirochetes in the general and at risk populations.

Detailed description: The intent of this protocol is to obtain blood, feces and urine samples from subjects with or without a suspected spirochaete infection, so these samples can be used in spirochaete-related scientific studies.

Eligibility criteria: Inclusion Criteria:

1. The subject must be able to be fully consented to the study.
2. The subject must be 18 years of age or older.
3. The subject must be mentally competent as determined by the Investigator.

Exclusion Criteria:

1. The subject must not be currently incarcerated or pregnant.
2. The subject must not weigh less than 110lbs.
3. If the subject will be contributing more that 60 ml of blood during an 8 (eight) week period, then the subject must not have donated red blood cells within the last 8 (eight) weeks.
4. If the Subject's health would be compromised by contributing up to 30ml of peripheral blood.
5. If in the opinion of the Investigator, the subject has any clinically significant medical diagnosis/conditions which would prevent participation.

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: Southwest Regional Wound Care Center
name: Randall Wolcott, MD
role: PRINCIPAL_INVESTIGATOR
References: